The first project presented here was generated around 1 calcitriol (1,25D₃), and novel low-calcemic analogues (VDAs). The hypothesis of this study was that VDAs may be effective in Diffuse Large B cell Lymphoma. It has been demonstrated that 1,25D₃ and certain VDAs displayed moderate cytotoxic and pro-apoptotic actions upon DLBCL cells. Additionally, 1,25D₃ and VDAs used in a combination with antidepressant clomipramine displayed concentration anti-stimulatory actions upon activated normal B-cells. The second part of the study is focused around a novel immunomodulator CX1001, data from which is currently confidential. The third project has been built around GPR61. I have demonstrated that myc-tagged GPR61 is expressed in the cell membrane and is subject to N-glycosylation. The N12S mutant of GPR61, which is not subject to N-glycosylation, is also expressed on the cell surface. Treating the cells with tunicamycin reduces cell membrane expression of non-mutated and mutated proteins. Furthermore, GPR61 mRNA and protein are expressed in white blood cells with significantly increased level of expression of the protein in Th17 cells.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:720735 |
| Date | January 2017 |
| Creators | Kozielewicz, Pawel |
| Publisher | University of Birmingham |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Source | http://etheses.bham.ac.uk//id/eprint/7638/ |
Page generated in 0.0019 seconds